Villers-lès-Nancy, 12 May 2025 - 6:00 PM (CET) PRESS RELEASE Q1 revenue at 31 March 2025: €57.0m+ 6.9% growth on a reported basis and + 5.9% like-for-like Q1 2025 REVENUE (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Equasens Group 53.357.03.76.9%0.53.25.9%Q1 2025 revenue / Division (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Pharmagest39.842.02.25.5% 2.25.5%Axigate Link7.88.30.45.5% 0.45.5%e-Connect2.93.50.621.2% 0.621.2%Medical Solutions2.12.70.525.1%0.50.00.0%Fintech0.60.6-0.1-8.3% -0.1-8.3%Total53.357.03.76.9%0.53.25.9% As of March 31, 2025, Equasens Group, (Euronext Paris™ - Compartment B - FR 0012882389 -EQS), a leading provider of digital solutions for healthcare professionals, reported revenue of €57.0m, up 6.9% on Q1 2024 reported basis and 5.9% like-for-like.
Q1 2025 revenue by type of business (€m)2024Reported basis2025Reported basisChange / Reported basisSale of configurations and hardware21.523.21.77.7%Scalable maintenance and professional training services19.720.30.73.5%Software solutions and subscriptions11.612.91.311.3%Other services (including intermediation)0.50.60.07.7%Total53.357.03.76.9% Q1 2025 highlights by type of business Sales of configurations and hardware (+7.7%) were back on track, after one year, with a trajectory of sustained growth for Pharmagest (+5.7%) and e-Connect (+68.4%), confirming the rebound announced in Q4 2024.
However, even if the trend is positive, certain segments remain cautious in terms of growth (e.g.electronic labels);The success of innovative new offerings such as id.genius (540 sales in Q1), id.vocal+ (55 sales) and id.care+ ;Digipharmacie (+41%), which is continuing to add new customers at a sustained pace and whose recently deployed new functionalities are driving the acceleration in growth that the Group has foreseen;Atoopharm (+23%), which has benefited from the end of three-year training scheme for healthcare professionals and the anticipated substitution of biosimilars.In Italy (revenue up 13.3%), the Division benefited from buoyant sales momentum (with almost 50 new customers in Q1), with a reinforced sales team that is now covering the entire country.
The story "Equasens: Q1 revenue at 31 March 2025" has 663 words across 22 sentences, which will take approximately 3 - 6 minutes for the average person to read.
Which news outlet covered this story?
The story "Equasens: Q1 revenue at 31 March 2025" was covered 14 hours ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 78 news stories per day.
It's most recent story was published 9 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Negative, indicating that people regard this as "bad news".
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
